Randomised clinical trial: vercirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease

  • B. G. Feagan, W. J. Sandborn, G. D'Haens, S. D. Lee, M. Allez, R. N. Fedorak, U. Seidler, S. Vermeire, I. C. Lawrance, A. C. Maroney, C. H. Jurgensen, A. Heath, D. J. Chang
  • Alimentary Pharmacology & Therapeutics (Suppl), September 2015, Wiley
  • DOI: 10.1111/apt.13398

The authors haven't yet claimed this publication.

Read Publication

http://dx.doi.org/10.1111/apt.13398

In partnership with: